News

Kiniksa Pharmaceuticals Shares Fall After Test Results

1 Mins read

Shares of Kiniksa Pharmaceuticals saw a decline on Thursday following disappointing test results from one of the company’s study cohorts. The stock was down 9.9% to $18 during midday trading, although it is still up 9.9% in the last three months.

Study Results and Clinical Effect

Kiniksa Pharmaceuticals, a biopharmaceutical company, announced on Thursday that the biweekly-dose level of one cohort in its Phase 2 clinical study of abiprubart for treating rheumatoid arthritis did not achieve statistical significance. However, the company reported positive clinical effects in the first three cohorts.

Cohort 3 Achieves Statistical Significance

Despite facing a high placebo response rate, Kiniksa highlighted that the 5mg/kg weekly dose level in Cohort 3 managed to achieve statistical significance. This discovery is significant given the challenging circumstances.

Determining Next Steps

Sanj Patel, Chief Executive of Kiniksa Pharmaceuticals, stated that they would analyze the comprehensive dataset to make informed decisions regarding the future of the program.

Study Breakdown

Cohort 3 formed a crucial part of the study’s proof-of-concept phase, while the initial two cohorts served as a lead-in to evaluate pharmacokinetics, safety, and tolerability. The company plans to release results from the fourth cohort sometime in the second quarter of 2024.

Related posts
News

North Korea Accused of Stealing Billions Through Cyberattacks to Fund Nuclear Program

3 Mins read
An international report reveals North Korea’s extensive cyber operations, detailing billions stolen through cryptocurrency theft, fake remote tech jobs, and malware, all…
News

The silent war: When virtual attacks inflict real-world devastation

3 Mins read
As digital transformation accelerates worldwide, cyberspace has become vital to the economy and society — but also a high-risk arena for data…
News

'Ether Caught Fire': ETH Surged as Capital Fled Bitcoin in Q3, CoinGecko Report Finds

2 Mins read
Ethereum (ETH) emerged as the frontrunner in crypto’s third-quarter recovery, leaving bitcoin (BTC) behind as capital flowed into altcoins, DeFi protocols, and…

Leave a Reply

Your email address will not be published. Required fields are marked *